Furthermore, the combination of anti-fibroblast growth factor receptor 4 (FGFR4) and anti-HER2 therapies has been identified as a mechanism to trigger ferroptosis in HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.